ArticleCureus2025
GLP-1 Receptor Agonist Use in Patients Undergoing Distal Radius Fracture Surgery: A Retrospective Review of Perioperative Considerations.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control and weight loss, but their effects on surgical outcomes remain incompletely understood. Delayed gastric emptying and associated perioperative risks have prompted updated anesthetic guidelines, although evidence in orthopaedic or hand surgery remains limited. This study aims to evaluate the prevalence of GLP-1 RA use and its perioperative implications among patients undergoing surgical fixation for distal radius fractures (DRFs).
methodsA retrospective review of 4,811 adult patients undergoing operative treatment for DRFs between 2019 and 2024 was conducted. GLP-1 RA use prior to surgery was identified through medication reconciliation. Demographics, comorbidities, medication type, and postoperative complications, including nausea, vomiting, abdominal pain, aspiration, emergency visits, and hospital readmissions, were assessed.
resultsGLP-1 RA use was observed in 46 patients (1.0%) over a six-year period, with prevalence rising from 0.4% to 0.5% annually between 2019 and 2022 (three to four patients each year) to 1.0% in 2023 (eight out of 808 patients) and to 2.9% in 2024 (23 out of 781 patients). Semaglutide was the most commonly used agent in the cohort. Only one GLP-1 user (2.2%, one out of 46) experienced postoperative nausea. There were no cases of aspiration or serious complications documented.
conclusionGLP-1 RA use among orthopaedic trauma patients is increasing, reflecting broader prescribing trends. In this cohort, perioperative complications were rare, although underreporting may be a factor. The retrospective nature of the study and the relatively small number of GLP-1 users limit the generalizability of the findings. Nonetheless, orthopaedic surgeons should be aware of potential anesthetic considerations, evolving guidelines, and the importance of coordinated perioperative planning as GLP-1 use expands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.